MedTrace Logo

Dexmedetomidine and Adenosine: Therapeutic Use for SVT

NCT01495481 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 22

Last updated 2017-03-28

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to evaluate the efficacy and safety of dexmedetomidine in the acute termination of Supraventricular Tachycardia (SVT).

Conditions

  • Supraventricular Tachycardia

Interventions

DRUG

Dexmedetomidine

Dexmedetomidine 2 mcg/kg, Intravenous push

DRUG

Adenosine

Stepwise incremental approach of adenosine starting at 0.2 mg/kg (max 6 mg) followed by 0.3 mg/kg (max 12 mg) if initial dose was unsuccessful

Sponsors & Collaborators

  • University of Pittsburgh

    lead OTHER

Principal Investigators

  • Gaurav Arora, MD · University of Pittsburgh

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
5 Years
Max Age
30 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-01-31
Primary Completion
2014-07-31
Completion
2014-07-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01495481 on ClinicalTrials.gov